Skip to main content
Clinical Trials/IRCT20200105046010N93
IRCT20200105046010N93
Recruiting
未知

Bioequivalence study of Empagliflozin/Metformin12.5/1000 mg ( EMZIP® 12.5/1000 mg) manufactured by Faran pharmed versus originator brand SYNJARDY® 12.5/1000 mg manufactured by ??Boehringer ????? Co in fasting condition in healthy volunteers

Faran Pharmed company0 sites24 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
This study is performed on healthy volunteers and drug concentration in plasma is determined..
Sponsor
Faran Pharmed company
Enrollment
24
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Faran Pharmed company

Eligibility Criteria

Inclusion Criteria

  • General Health (Liver, Heart, and Kidney)
  • Body Mass Index (18\-28\)
  • Informed consent
  • Age (18\-55 years old)

Exclusion Criteria

  • History of cardiovascular disease
  • History of liver and kidney disease
  • Alcoholism and Narcoticism
  • History of allergy to Empagliflozin/Metformin

Outcomes

Primary Outcomes

Not specified

Similar Trials